Article

Orange Book Listing Opportunities for Drug-Device Combinations

Authors

By: Terry G. Mahn, Michael A. Siem, and Elizabeth M. Flanagan

BNA Pharmaceutical Law & Industry Report, 9 PLIR 1500, 12/02/2011.

With many blockbuster drugs coming off patent in the next several years, Branded Pharmaceutical Companies are looking for more and more ways to protect their products. Increasingly, such companies are listing patents covering medical devices integral to drug delivery in the Orange Book as a means to do so.  As described below this practice appears to be proper and presents an intriguing strategy to protect market share.

To continue reading the article, click here.

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.